经中国证券监督管理委员会《关于同意厦门金达威集团股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2024〕1567 号）同意， 厦门金达威集团股份有限公司（以下简称"公司"）向不特定对象发行面值总额 129,239.48 万元可转换公司债券，期限 6 年，每张面值为人民币 100 元，发行数 量 12,923,948 张，募集资金总额为人民币 1,292,394,800.00 元。扣除保荐承销费、 专项审计及验资费、律师费等发行费用（不含增值税）共计人民币 11,136,143.56 元后，募集资金净额为人民币 1,281,258,656.44 元。其中，扣除保荐承销费人民 币 8,849,692.44 元（含增值税）后的募集资金余额为人民币 1,283,545,107.56 元， 已由保荐人（主承销商）广发证券股份有限公司（以下简称"广发证券"）于 2025 年 8 月 26 日汇入公司指定的募集资金专项账户（以下简称"募集资金专户"）。 | 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：12711 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 经调整，本次向不特定对象发行可转换公司债券的募投项目及募集资金使用计划 如下： 单位：万元 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日召 开第九届董事会第六次会议，审议通过《关于使用部分闲置募集资金暂时补充流 动资金的议案》，同意公司在确保不影响募投项目建设的前提下，使用不超过 5 亿元的闲置募集资金暂时补充流动资金，该资金仅限使用于与公司主营业务相关 的生产经营（包括但不限于支付生产采购付款、日常经营费用和偿还流动资金贷 款等），补充流动资金的期限自董事会审议通过之日起不超过 12 个月。 该事项在股东会授权董事会全权办理本次向不特定对象发行可转换公司债 券具体事宜的范围之内，无需再提交股东会审议。现将相关情况公告如下 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于调整募投项目拟投入募集资金金额的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日召 开第九届董事会第六次会议，审议通过《关于调整募投项目拟投入募集资金金额 的议案》，同意公司根据实际募集资金情况，对募投项目拟投入募集资金金额进 行调整。该事项在股东会授权董事会全权办理本次向不特定对象发行可转换公司 债券具体事宜的范围之内，无需再提交股东会审议。现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意厦门金达威集团股份有限公 司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕1567 号）， 公司于 2025 年 8 月 20 日向不特定对象发行了 12,923,948 张可转换公司债券，发 行价格为每张 100 元， ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于聘任副总经理、董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日召 开第九届董事会第六次会议审议通过《关于聘任副总经理、董事会秘书的议案》， 经公司董事长提名，董事会提名委员会审查通过，董事会同意聘任李晓芳女士为 公司副总经理、董事会秘书（简历附后），任期自本次会议审议通过之日起至第 九届董事会任期届满之日止。 李晓芳女士具备履行职责所必须的专业能力和工作经验，并已取得深圳证券 交易所颁发的《上市公司董事会秘书培训证明》，符合《公司法》《深圳证券交 易所上市公司自律监管指引第 1 号—主板上市公司规范运作》《深圳证券交易所 股票上市规则》和《公司章程》等相关规定。 李晓芳女士的联系方式如下： 电话：0592-3781760 邮箱：xiaofang.li@ ...

Core Points - Company exercised its preferential subscription rights to participate in the issuance of convertible bonds by Xiamen Jindawei Group Co., Ltd [1][2] - The company subscribed to 2,414,012 convertible bonds at a price of 100 yuan per bond, totaling 24,140.12 million yuan [1] - Jindawei announced that the entire subscription amount was fully allocated and the bonds will be listed on the Shenzhen Stock Exchange starting September 8, 2025 [2] Group 1 - The company held a board meeting on August 18, 2025, to approve the participation in the bond issuance [1] - The subscription was executed through the Shenzhen Stock Exchange trading system on August 20, 2025 [1] - The company commits to not reducing its holdings in Jindawei's stock and the newly issued convertible bonds for six months from the issuance date [2]

Core Viewpoint - Xiamen Jindawei Group Co., Ltd. has received a patent for a method and device for preparing 7-dehydrocholesterol and vitamin D3, which enhances the yield and purity of 7-dehydrocholesterol, contributing to the company's technological innovation and intellectual property protection [1][2]. Summary by Relevant Sections - **Patent Details** - Patent Name: A method and device for preparing 7-dehydrocholesterol and vitamin D3 [1] - Patent Number: ZL 2023 1 0125624.5 [1] - Application Date: February 16, 2023 [1] - Patent Holder: Xiamen Jindawei Vitamin Co., Ltd. [1] - Patent Term: Twenty years [1] - Certificate Number: 8222940 [1] - Authorization Announcement Date: September 5, 2025 [1] - **Technical Significance** - The invention belongs to the field of organic synthesis and aims to improve the yield and purity of 7-dehydrocholesterol [1]. - **Impact on Company** - The acquisition of the patent is not expected to have a significant impact on the company's production and operations but is beneficial for technological innovation and enhancing core competitiveness through intellectual property [1].

Core Viewpoint - The company, Jindawei, announced the receipt of a patent for a method and device for preparing 7-dehydrocholesterol and vitamin D3, which may enhance its product offerings and competitive position in the market [1] Group 1 - Jindawei and its subsidiary, Xiamen Jindawei Vitamin Co., Ltd., received a patent certificate from the National Intellectual Property Administration [1] - The patent is for an invention titled "A method and device for preparing 7-dehydrocholesterol and vitamin D3" [1]

Core Viewpoint - Kingdawei (002626.SZ) has recently received a patent certificate from the National Intellectual Property Administration for a method and device for the preparation of 7-dehydrocholesterol and vitamin D3 [1] Group 1 - The patent pertains to an innovative preparation method for 7-dehydrocholesterol and vitamin D3, which may enhance the company's product offerings and competitive edge in the market [1]

Investment Rating - The report rates the health supplement industry as "Outperform" [1] Core Insights - The health supplement industry is entering a new upward cycle, driven by rising health awareness among younger consumers and the emergence of new consumption trends [6][9] - The market for nutritional health products in China is projected to reach 522.3 billion yuan by 2024, with a compound annual growth rate of 5.7% from 2019 to 2024 [10][11] - Online sales channels are becoming increasingly important, with a significant rise in sales through platforms like Douyin, which has become the leading online sales platform for health supplements [32][35] Summary by Sections Industry Characteristics - The industry is characterized by a clear trend towards younger consumers, the emergence of new niche markets, and accelerated product iteration [7][9] - The overall scale of the traditional health supplement market is over 300 billion yuan, growing at approximately 5% annually, while new consumption segments such as anti-aging and cardiovascular health are emerging [9] Market Dynamics - The online sales of health supplements in China grew from 107.4 billion yuan in 2022 to 142.1 billion yuan in 2023, indicating a strong shift towards e-commerce [29][30] - Douyin's sales growth in health supplements reached 38% in the first half of 2025, surpassing other platforms like Tmall and JD [32] Key Segments - The report identifies several high-growth segments within the health supplement industry: - Anti-aging: Focused on products like ergothioneine and NAD+ [49][52] - Sports nutrition: Emphasizing glucosamine and calcium products [55] - Cardiovascular health: Highlighting deep-sea fish oil and phospholipid products [58] - Liver health: Addressing needs arising from unhealthy lifestyles [61] - Probiotics: Targeting gut health and overall wellness [66] Investment Recommendations - The report suggests focusing on brands with strong product operation capabilities and high brand recognition, such as Ruoyuchen and H&H International Holdings [5][69] - For production, it recommends selecting leading companies with substantial scale and customer resources, such as Xianle Health [5][69] - In the raw material sector, it highlights industry leaders like Jindawei [5][69]

Market Overview - On September 5, the food processing sector rose by 0.68% compared to the previous trading day, with Baihe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Baihe Co., Ltd. (603102) closed at 46.51, with a significant increase of 10.00% and a trading volume of 35,200 hands, amounting to a transaction value of 160 million yuan [1] - Other notable performers included Kangbiter (833429) with a 4.39% increase, and Tangchen Beijian (300146) with a 2.26% increase [1] Capital Flow - The food processing sector experienced a net outflow of 48.96 million yuan from institutional investors, while retail investors saw a net outflow of 83.72 million yuan [2] - Conversely, speculative funds recorded a net inflow of 133 million yuan [2] Individual Stock Capital Flow - Baihe Co., Ltd. had a net inflow of 42.73 million yuan from institutional investors, but a net outflow of 20.46 million yuan from retail investors [3] - Guangming Meat Industry (600073) also saw a net inflow of 23.86 million yuan from institutional investors, with retail investors experiencing a net outflow of 20.24 million yuan [3]